Now Available:
Download the podcast of Dr. Sobell's presentation

With biweekly and special edition newsletters, Musculoskeletal Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.

MSK Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts. With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.

MSK Video Report:


Dr. Jeffrey M. Sobell presents "Long-Term Management of Patients with Psoriasis" from our 5-part series, "Practical Approaches to Solving Psoriasis Challenges"

Bones: Loop Diuretics Pose Osteoporosis Risk for Older Men
Loop diuretics greatly increase hip bone loss in men over age 65...

Consumer News: New Psoriasis Pill Appears Effective
An oral dose of ISA247, a calcineurin inhibitor, shows promise as a safe and effective treatment for moderate to severe psoriasis...

New from PubMed: Pain Management in Fibromyalgia
New treatments targeting central pain mechanisms may benefit patients suffering from chronic pain...

BioPharm Business: Roche's Actemra (tocilizumab) Approved in Japan to Treat Patients With RA; Represents First Approval for Actemra in RA Worldwide
Roche partner company Chugai Pharmaceutical Co, Ltd has received approval in Japan for Actemra (tocilizumab) 200 mg for the treatment of rheumatoid arthritis, making Japan the first market to gain access to Actemra for the treatment of RA...

BioPharm Business: Abbott's Humira (adalimumab) Approved in Japan for the Treatment of RA
Abbott received approval in Japan for Humira (adalimumab) to treat RA in patients with inadequate response to conventional therapy...

BioPharm Business: Novartis Announces Once-Yearly Reclast Better Than Risedronate at Increasing BMD in GIO Patients; US FDA Approval Sought for Treatment and Prevention of GIO
Novartis Pharmaceuticals Corp reported that a once-yearly infusion of Reclast (zoledronic acid) injection 5 mg was significantly better than risedronate at increasing BMD in patients with glucocorticoid-induced osteoporosis...

Click here to remove your e-mail address from our mailing list. For questions and comments regarding this newsletter please contact .